So far, treatment options for patients with higher risk myelodysplastic syndromes (MDS) have been quite limited. For azacitidine, a pyrimidine analogue with antineoplastic activity, increased survival rates for intermediate-2 to high-risk MDS patients in comparison to the three other most common forms of treatment were demonstrated in a phase III study. Hence, it provides a valuable treatment option for these difficult to treat patients.